These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 16452391)

  • 1. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.
    Cha HS; Boyle DL; Inoue T; Schoot R; Tak PP; Pine P; Firestein GS
    J Pharmacol Exp Ther; 2006 May; 317(2):571-8. PubMed ID: 16452391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
    Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
    J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Jun N-terminal kinase in rheumatoid arthritis.
    Han Z; Boyle DL; Aupperle KR; Bennett B; Manning AM; Firestein GS
    J Pharmacol Exp Ther; 1999 Oct; 291(1):124-30. PubMed ID: 10490895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of JNK by MKK-7 in fibroblast-like synoviocytes.
    Inoue T; Hammaker D; Boyle DL; Firestein GS
    Arthritis Rheum; 2006 Jul; 54(7):2127-35. PubMed ID: 16802349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial fibroblasts.
    Mun SH; Kim JW; Nah SS; Ko NY; Lee JH; Kim JD; Kim DK; Kim HS; Choi JD; Kim SH; Lee CK; Park SH; Kim BK; Kim HS; Kim YM; Choi WS
    Arthritis Rheum; 2009 Mar; 60(3):678-85. PubMed ID: 19248119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and activation of mitogen-activated protein kinase kinases-3 and -6 in rheumatoid arthritis.
    Chabaud-Riou M; Firestein GS
    Am J Pathol; 2004 Jan; 164(1):177-84. PubMed ID: 14695331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.
    Han Z; Boyle DL; Chang L; Bennett B; Karin M; Yang L; Manning AM; Firestein GS
    J Clin Invest; 2001 Jul; 108(1):73-81. PubMed ID: 11435459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis.
    Hammaker DR; Boyle DL; Chabaud-Riou M; Firestein GS
    J Immunol; 2004 Feb; 172(3):1612-8. PubMed ID: 14734742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
    Lin YC; Huang DY; Chu CL; Lin WW
    Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the MAPK kinases MKK-4 and MKK-7 in rheumatoid arthritis and their role as key regulators of JNK.
    Sundarrajan M; Boyle DL; Chabaud-Riou M; Hammaker D; Firestein GS
    Arthritis Rheum; 2003 Sep; 48(9):2450-60. PubMed ID: 13130464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis.
    Kunisch E; Gandesiri M; Fuhrmann R; Roth A; Winter R; Kinne RW
    Ann Rheum Dis; 2007 Aug; 66(8):1043-51. PubMed ID: 17223661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spleen tyrosine kinase mediates BEAS-2B cell migration and proliferation and human rhinovirus-induced expression of vascular endothelial growth factor and interleukin-8.
    Wang X; Mychajlowycz M; Lau C; Gutierrez C; Scott JA; Chow CW
    J Pharmacol Exp Ther; 2012 Feb; 340(2):277-85. PubMed ID: 22031919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
    Spalton JC; Mori J; Pollitt AY; Hughes CE; Eble JA; Watson SP
    J Thromb Haemost; 2009 Jul; 7(7):1192-9. PubMed ID: 19422460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
    Pine PR; Chang B; Schoettler N; Banquerigo ML; Wang S; Lau A; Zhao F; Grossbard EB; Payan DG; Brahn E
    Clin Immunol; 2007 Sep; 124(3):244-57. PubMed ID: 17537677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of spleen tyrosine kinase (Syk) at fertilization in Rhinella arenarum eggs.
    Mouguelar VS; Coux G
    Int J Dev Biol; 2014; 58(10-12):811-8. PubMed ID: 26154322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies.
    Lhermusier T; van Rottem J; Garcia C; Xuereb JM; Ragab A; Martin V; Gratacap MP; Sié P; Payrastre B
    J Thromb Haemost; 2011 Oct; 9(10):2067-76. PubMed ID: 21848694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of benzylidene derivatives as potent Syk inhibitors: synthesis, SAR analysis, and biological evaluation.
    Zhang L; Liu W; Mao F; Zhu J; Dong G; Jiang H; Sheng C; Miao L; Huang L; Li J
    Arch Pharm (Weinheim); 2015 Jul; 348(7):463-74. PubMed ID: 26032727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
    Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
    Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-1 and TNF induction of matrix metalloproteinase-3 by c-Jun N-terminal kinase in trabecular meshwork.
    Hosseini M; Rose AY; Song K; Bohan C; Alexander JP; Kelley MJ; Acott TS
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1469-76. PubMed ID: 16565381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.